Efferon, a startup recognized in TechCrunch Disrupt 2026’s Startup Battlefield 200, is developing innovative blood-purification devices aimed at reducing the lethal impact of pediatric sepsis. Sepsis leads to the death of about 3 million children under five each year, caused by an overwhelming immune response to infection that damages vital organs. When antibiotics fail to control this immune system overreaction, Efferon's technology steps in to filter out harmful cytokines and toxins from the blood, targeting both simultaneously, unlike existing solutions.

The company's pediatric-specific device, Efferon NEO, is designed to accommodate children's smaller blood volumes and physiological needs. This device is already in use in intensive care units across 30 countries, including Europe, Saudi Arabia, and Thailand. In April, Efferon NEO received the CE mark, the European approval equivalent to the FDA’s clearance, marking it as the first multimodal extracorporeal blood purification system targeted specifically at pediatric patients suffering from sepsis.

Efferon's technology originates from research by scientists at Moscow State University, where co-founder Ivan Bessonov helped pioneer the innovation. Serial entrepreneur Dima Romashin took over as CEO earlier in 2026 to spearhead the company’s commercialization efforts. While growth has been steady rather than rapid, the company expects to reach $2 million in annualized revenue by the end of this year, focusing on long-term impact over speed.

The ultimate goal for Efferon goes beyond financial success; it aims to save children’s lives by enabling faster recovery from sepsis-induced organ failure. Romashin emphasizes that every child able to return home is a true measure of the company's achievements, reflecting a mission-driven approach to tackling one of the most critical causes of pediatric mortality worldwide. The company is currently preparing to apply for FDA approval to expand its reach further.